Prednimustine therapy for advanced prostatic cancer
- PMID: 630199
- DOI: 10.1111/j.1464-410x.1978.tb02761.x
Prednimustine therapy for advanced prostatic cancer
Abstract
23 patients with advanced, hormonal-resistant, prostatic cancer were treated with daily oral prednimustine--a combination of prednisolone and chlorambucil. 8 patients (35%) subjectively responded with disappearance of skeletal pain and improvement in appetite, weight and sense of well being. 3 patients had objective evidence of tumour regression. Clinical toxicity was moderate, and only occasional myelosuppression was encountered. The ease of administration and predictable toxicity of prenimustine make it a potentially useful agent, alone or in combination, for advanced prostatic cancer.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources